A Safety Study in Participants With Major Depressive Disorder

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in participants with major depressive disorder (MDD) who are partial responders to their SSRI treatment.

Timeline

Start

2010-10

Primary completion

2012-12

Completion

2012-12

Drugs

Indications